Pharma Update

Immunology, Infectious Disease and CVM pipeline Gazyva Ph III data in lupus nephritis expected in 2024; zilebesiran in hypertension added Ph I (8 NMEs) Ph II (8 NMEs) Ph III (1 NMEs, 7 AI) Roche RG6107 crovalimab LN will RG6299 ASO factor B IgA nephropathy RG3648 Xolair Food allergy RG6287 undisclosed aGVHD undisclosed RG6341 RG6149 Chronic cough astegolimab (Anti-ST2) COPD RG6315 undisclosed Immunological disorders Vixarelimab RG6536 RG7159 Gazyva IPF/SSC-ILD Lupus nephritis RG6421 TMEM16A potentiator cystic fibrosis RG7854/RG63 ruzotolimod/xalnesiran/PDL1LNA 46/RG6084 HBV Gazyva RG7159 Membranous nephropathy Lunsumio (mosunetuzumab) RG7828 RG7159 SLE SPK-3006 Gazyva SLE RG6359 Pompe disease CHU anti-HLA-DQ2.5x gluten peptides Celiac disease RG7159 RG6615 zilebesiran Hypertension Gazyva Childhood onset INS CHU RAY121 Immunology RG7159 Xofluza Influenza, pediatric RG6006 ABX MCP bacterial infections RG7845 Xofluza Influenza direct transmission RG6319 LepB inhibitor complicated urinary tract infection RG6449 HBsAg MAb Chronic hepatitis B Immunology Small molecule Infectious diseases Antibody Cardiovascular & metabolism Locked nucleic acid / antisense Gene therapy Upcoming readouts Ph III (REGENCY) Gazyva in LN data expected in 2024 Ph II (KARDIA-2) zilebesiran as add-on to one SoC in uncontrolled hypertension data expected early 2024 NME=new molecular entity; Al-additional indication; LN-lupus nephritis; SLE-Systemic lupus erythematosus; aGVHD=Acute graft-versus-host disease; COPD-Chronic obstructive pulmonary disease; HBV= Hepatitis B virus; INS-idiopathic nephrotic syndrome; IPF-idiopathic pulmonary fibrosis; SSC-ILD=systemic sclerosis-interstitial lung disease 110

View entire presentation